Endocrine Abstracts

Resistance to newly developed androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, rapidly emerges and patients generally die within 2 years. In particular, a subset of patients who relapse following ARPI therapy exhibit lineage switching whereby tumours shed their dependence on AR signaling and emerge with neuroendocrine features. These tumours, termed treatment induced neuroendocrine prostate cancer (t-NEPC), carry an extremely poor prognosis a...

Lineage plasticity has been postulated to contribute to the failure of targeted- and immuno-therapies. In prostate cancer (PCa), the discovery that advanced metastatic castration-resistant PCa (CRPC) classified as adenocarcinoma remains fueled by the androgen receptor (AR) has ushered the development of potent AR pathway inhibitors (ARPIs), notably abiraterone and enzalutamide undoubtedly benefiting the survival of patients with advanced disease. However, a subset of patients ...